Eosinophil-mast cell interaction: Mepolizumab leads to a reduction of clinical symptoms and serum tryptase in a patient with eosinophilic asthma and idiopathic mast cell activation.

Guillet, Carole; Steinmann, Simona; Lang, Claudia; Maul, Julia-Tatjana; Schmid-Grendelmeier, Peter

Guillet, Carole; Steinmann, Simona; Lang, Claudia; Maul, Julia-Tatjana; Schmid-Grendelmeier, Peter.

Afiliação

Guillet C; Allergy Unit, Department of Dermatology, University Hospital Zurich, Zurich, Switzerland. Electronic address: carole.guillet@usz.ch.
Steinmann S; Allergy Unit, Department of Dermatology, University Hospital Zurich, Zurich, Switzerland.
Lang C; Allergy Unit, Department of Dermatology, University Hospital Zurich, Zurich, Switzerland.
Maul JT; Allergy Unit, Department of Dermatology, University Hospital Zurich, Zurich, Switzerland.
Schmid-Grendelmeier P; Allergy Unit, Department of Dermatology, University Hospital Zurich, Zurich, Switzerland.

J Allergy Clin Immunol Pract ; 9(3): 1393-1395.e1, 2021 03.

Article em En | MEDLINE | ID: mdl-33096266

Assuntos

Anticorpos Monoclonais Humanizados/uso terapêutico; Asma; Eosinófilos; Asma/tratamento farmacológico; Humanos; Mastócitos; Triptases

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Bases de dados: MEDLINE Assunto principal: Asma / Eosinófilos / Anticorpos Monoclonais Humanizados Tipo de estudo: Diagnostic_studies Limite: Humans Idioma: En Revista: J Allergy Clin Immunol Pract Ano de publicação: 2021 Tipo de documento: Article

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google